Concomitant <i>KIT/BRAF</i> and <i>PDGFRA/BRAF</i> mutations are rare events in gastrointestinal stromal tumors

Abstract

The concomitance of BRAF mutation with either KIT or PDGFRA mutation is rare in GIST. In these tumors, moderate/strong VE1 immunoreactivity is a valuable surrogate for molecular analysis. Instead, genotyping is warranted in the presence of weak VE1 staining.